Ketamine Therapy in Utah

Ketamine therapy in Utah operates under a well-established federal and state regulatory framework. At the federal level, ketamine is classified as a Schedule III controlled substance under the Controlled Substances Act, meaning that any provider administering or prescribing ketamine must hold a valid DEA registration. Utah state law aligns with federal standards, and all ketamine clinics operating within the state must comply with regulations set forth by the Utah Department of Commerce, Division of Occupational and Professional Licensing (DOPL), which oversees the licensure of physicians, nurse practitioners, and other healthcare professionals authorized to prescribe and administer controlled substances.

In Utah, ketamine infusions for conditions such as treatment-resistant depression, PTSD, chronic pain, and anxiety are legally administered in clinical settings under the supervision of a licensed medical professional. The most common providers include:

• Medical doctors (MDs) and doctors of osteopathic medicine (DOs)
• Advanced practice registered nurses (APRNs) with prescriptive authority
• Certified registered nurse anesthetists (CRNAs) in appropriate clinical contexts
• Physician assistants (PAs) operating under physician supervision

It is important to note that ketamine infusion therapy is not currently FDA-approved for psychiatric indications such as depression, meaning its use in mental health treatment is considered off-label. However, esketamine (Spravato), a ketamine-derived nasal spray, has received FDA approval for treatment-resistant depression and major depressive disorder with suicidal ideation, and is available through certified healthcare providers in Utah under a Risk Evaluation and Mitigation Strategy (REMS) program. Patients seeking either form of treatment should verify that their chosen clinic employs properly credentialed staff and maintains compliance with all applicable state and federal regulations.

Utah does not currently have state-specific legislation uniquely governing ketamine clinics beyond general controlled substance and medical practice laws, but providers are expected to adhere to evolving best-practice guidelines issued by professional organizations such as the American Society of Ketamine Physicians, Psychotherapists and Practitioners (ASKP3) and the American Society of Anesthesiologists (ASA). Patients are encouraged to ask prospective clinics about their protocols for patient screening, informed consent, monitoring during infusions, and follow-up care, as these standards help ensure both safety and treatment efficacy.